Next-generation regenerative medicine: a benefit for public health and welfare, a driver of the next industrial revolution starting from Japan.
Organ Technologies was founded to spark a new industrial revolution starting from Japan which is one of the health care’s hottest growth fields: regenerative medicine. Our mission is to promote the health and welfare of people all over the world through our novel bioengineering technologies designed to produce realistic organs that are functionally equivalent to natural ones.
Regenerative medicine refers to a number of treatments based on cells and tissues of human origin, designed for patients ill-served by conventional ones. Organ replacement regeneration is an eagerly anticipated paradigm in the field, i.e., replacing entire organs no longer functioning due to disease or injury with new ones artificially grown outside the body. Along with Dr. Takashi Tsuji, PhD of RIKEN, we developed the “organ germ method,” a world-first technique to reconstitute organ germ tissue by manipulating cells, using biological systems for organ regeneration and engineering technology. Our goal is to utilize these technologies to meet the needs of many patients who have placed their hopes in regenerative medicine and organ transplantation.
Japan’s role in the global order has once again been called into question by changes in the structures of society and industry due to globalization. Our continued scientific and technical research is done in the hopes of not only building a clear future for Japan in the 21st century, but also making international contributions to human happiness everywhere, and creating technologies that can be handed down to later generations. To realize our vision, we believe it is the responsibility of the current generation to catalyze a new “industrial revolution” starting from Japan in the field of medicine. Regenerative medicine remains primarily the domain of small research teams, who painstakingly create single or small batches of products on a small scale. We believe this “craft production” approach lacks enough power to spark further innovation in regenerative medicine as an industry.
Tracing back the history of the (first) Industrial Revolution, one can see that mechanization and upscaling were crucial to industrialization. Since our company’s efforts alone would be insufficient to drive the same transformation in regenerative medicine, we are actively seeking partnerships with many companies who sympathize our vision to pave the way for the regenerative medicine industry.
Our basic research in regenerative technologies and our sure progress toward clinical applications are driven by the unflinching dedication of all of us at Organ Technologies toward a common goal: to improve the health and welfare, and indeed the happiness of people everywhere.
President Yasuhiro Sugimura, August 2017